Purified Membrane Proteins
CALIXAR’s KCC2 (Neuron-specific K-Cl Cotransporter) aids in the exploration, advancement, and validation of new molecules as well as therapeutic antibodies. They are ideal candidates for neurological disorders including pain and epilepsy.
KCC2 (potassium chloride co-transporter 2) are powerful therapeutic targets especially in the treatment of such conditions including pain and epilepsy.
This plasma membrane neuron-specific chloride potassium symporter is responsible for establishing the chloride ion gradient in neurons through the maintenance of low intracellular chloride concentrations.
It is a critical mediator of synaptic inhibition, cellular protection against excitotoxicity and may also act as a modulator of neuroplasticity.
Why choose us?
CALIXAR’s KCC2 (potassium chloride cotransporter 2) facilitates reliable fragment-based drug design (FBDD), structure-based drug discovery (SBDD) and antibody discovery against this specific target.
Unlike Calixar’s KCC2, other possible methods result in a potassium chloride cotransporter that becomes mutated and truncated (96 amino-acids at the C-terminus). In addition, this mutated version converts to a locked conformation within an antagonist.
As with all co-transporters and ion channels, KCC2 are unstable targets and are difficult to produce natively with conventional procedures. Traditionally, the KCC2 was never isolated from the membrane without causing aggregates due to its unstable construction.
Contrarily, Calixar’s co-transporters are the only original native and purified KCC2 on the market as it has been shown to be active in electrophysiology and thallium assays.
Our purified KCC2 membrane protein can bind to antagonist compounds using SPR. This preparation permits the first functional architecture of KCC2 reported up to date (Agez M. et al., 2017, Scientific Reports).
Our KCC2 co-transporters maintain their structural and functional integrity and are purified and stabilized to full length and wild-type (native) proteins. They are pure, native, and unaltered, with the ability to bind to an open and wide range of compounds including agonists, antagonists, and allosteric modulators.
CALIXAR’s KCC2 (potassium chloride cotransporter 2) is the first native full-length and functional target on the market. Other existing KCC2 targets are either mutated or truncated. Our KCC2 protein is produced in a eukaryotic system with the customary post-translational modifications (glycosylation), which gives us the ability to modify the buffer condition.
CALIXAR’s KCC2 (potassium chloride cotransporter 2) are high-quality membrane proteins used for pharmaceutical discovery and are adapted for use in biotechnology companies, as are also used by academic teams that are involved in the life science fields.
Agez M et al. 2017
discovery on target
Jawhari A. Boston, 2015
Desuzinges Mandon E. et al. 2017